Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Non-seminomatous germ cell tumour, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
2 medicines on record are linked to one of the types below rather than to Non-seminomatous germ cell tumour itself. Grouped by the type that holds them; each list opens that type's own page.
Poor-risk disease still kills about half of those affected.
Whether high-dose chemotherapy is better than conventional salvage (TIGER).
Cardiovascular disease, hearing loss and neuropathy in long-term survivors.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
Three-year progression-free survival 59 percent with marker-guided dose-dense chemotherapy against 48 percent with BEP (hazard ratio 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.